Safety, immunogenicity, and excretion pattern of single-dose live oral cholera vaccine CVD 103-HgR in Peruvian adults of high and low socioeconomic levels

Infect Immun. 1993 Sep;61(9):3994-7. doi: 10.1128/iai.61.9.3994-3997.1993.

Abstract

Groups of 122 Peruvian adults of low socioeconomic level (SEL) and 125 of high SEL received a randomly allocated 5 x 10(9)- or 5 x 10(8)-CFU dose of CVD 103-HgR live oral cholera vaccine or a placebo. The vaccine was well tolerated. Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Administration, Oral
  • Adult
  • Antibodies, Bacterial / blood*
  • Cholera Vaccines / administration & dosage
  • Cholera Vaccines / adverse effects
  • Cholera Vaccines / immunology*
  • Double-Blind Method
  • Humans
  • Peru
  • Socioeconomic Factors
  • Vaccination
  • Vibrio cholerae / immunology*

Substances

  • Antibodies, Bacterial
  • Cholera Vaccines